Adenosine Antagonists - Pipeline Insight, 2024

Adenosine Antagonists - Pipeline Insight, 2024

DelveInsight’s, “Adenosine Antagonists- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Adenosine Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Adenosine Antagonists: Understanding

Adenosine Antagonists: Overview

Adenosine is a naturally occurring nucleoside and an essential component of the energy production and utilization systems of the body. Adenosine is formed by the degradation of adenosine-triphosphate (ATP) during energy-consuming processes. ATP acts as a neurotransmitter in both peripheral and central nervous systems. Adenosine has been traditionally considered an inhibitor of neuronal activity and a regulator of cerebral blood flow. Since adenosine is neuroprotective against excitotoxic and metabolic dysfunctions observed in neurological and ocular diseases, the search for adenosine related drugs regulating adenosine transporters and receptors can be important for advancement of therapeutic strategies against these diseases.

Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. There are four known subtypes of adenosine receptors (ARs) – referred to as A1, A2A, A2B and A3 – each of which has a unique pharmacological profile, tissue distribution and effector coupling. All four subtypes are members of the superfamily of G-protein-coupled receptors (GPCRs), and are most closely related to the receptors for biogenic amines. Among the human ARs, the most similar are the A1 and A3 ARs (49% sequence similarity) and the A2A and A2B ARs (59% similarity). Selective antagonists have entered clinical trials for the treatment of Parkinson’s disease and congestive heart failure. Both in the case of diseases such as stroke, where there is an unmet medical need, and for diseases that already have pharmacological intervention options, the introduction of adenosine-based drug therapy will provide novel mechanisms for therapy.

""Adenosine Antagonists- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenosine Antagonists pipeline landscape is provided which includes the disease overview and Adenosine Antagonists treatment guidelines. The assessment part of the report embraces, in depth Adenosine Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenosine Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Adenosine Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Adenosine Antagonists.

Adenosine Antagonists Emerging Drugs Chapters

This segment of the Adenosine Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adenosine Antagonists Emerging Drugs

Etrumadenant: Arcus Biosciences

Etrumadenant, being developed by Arcus Biosciences, is a dual adenosine A2A and A2B receptor antagonists. Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation. The A2a/A2b receptors, expressed on the surface of immune cells, mediate the immunosuppressive effects of adenosine. It is currently in Phase II stage of development for the treatment of Non-small cell lung cancer and colorectal cancer.

Ciforadenant: Corvus Pharmaceuticals

Ciforadenant (CPI-444) is an investigational small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor. Adenosine, a metabolite of ATP (adenosine tri-phosphate), is produced within the tumor microenvironment where it may bind to the adenosine A2A receptor present on immune cells and block their activity. Currently, the drug is in the Phase II stage of its development for the treatment of renal cell carcinoma.

INT-1B3: InteRNA Technologies

INT-1B3 directly targets tumor cells and the tumor microenvironment by specific modulation of multiple signaling pathway components across the PTEN tumor suppressor pathway and the oncogenic PI3K/Akt and Ras/MAPK pathways resulting in cell cycle arrest, induction of apoptosis and immunogenic tumor cell death (ICD); as well as downregulation of the adenosine-A2A receptor pathway and immunosuppressive FoxP3/Lag3 Tregs and monocytic myeloid-derived suppressor cells (mMDSCs). As a result, the immune system is activated, and long-term immunity is triggered by recruitment of CD8+ Teffs leading to decreased metastasis development and improved animal survival compared to anti-PD1 treatment. The created T cell-mediated immune response activity is also transferrable to naive mice via adoptive T cell transfer. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of solid tumors.

Further product details are provided in the report……..

Adenosine Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Adenosine Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Adenosine Antagonists

There are approx. 20+ key companies which are developing the therapies for Adenosine Antagonists. The companies which have their Adenosine Antagonists drug candidates in the most advanced stage, i.e. Phase II include, Arcus Biosciences.

Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Adenosine Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adenosine Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenosine Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenosine Antagonists drugs.

Adenosine Antagonists Report Insights

Adenosine Antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Adenosine Antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Adenosine Antagonists drugs?

How many Adenosine Antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adenosine Antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenosine Antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Adenosine Antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Arcus Biosciences

Corvus Pharmaceuticals

InteRNA Technologies

Portage Biotech

AstraZeneca/Nxera Pharma

Bayer

Key Products

Etrumadenant

Ciforadenant

INT-1B3

PORT-6

Imaradenant

BAY-2880376

PORT 7